2018 / 02

Next Paper
DOI: 10.24075/brsmu.2018.025

ORIGINAL RESEARCH

Changes in the sensitivity of human glioblastoma cells to oncolytic enteroviruses induced by passaging

Soboleva AV1,2, Lipatova AV1, Kochetkov DV1, Chumakov PM2
About authors

1 Engelhardt Institute of Molecular Biology, Moscow

2 Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow

Correspondence should be addressed: Peter M. Chumakov
ul. Vavilova 32, Moscow, 119991; moc.oohay@mpvokamuhc

About paper

Funding: this work was supported by the Ministry of Education and Science of the Russian Federation (Project ID RFMEFI60714X0014).

Received: 2018-06-16 Accepted: 2018-07-22 Published online: 2018-07-08
|
  1. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008; 359 (5): 492–507.
  2. Mirimanoff RO, Gorlia T, Mason W, Van den Bent MJ, Kortmann RD, Fisher B, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol. 2006; 24 (16): 2563–2569. DOI: 10.1200/ JCO.2005.04.5963. PubMed PMID: 16735709.
  3. Sosnovtceva AO, Grinenko NF, Lipatova AV, Chumakov PM, Chekhonin VP. Onkoliticheskie virusy v terapii zlokachestvennih gliom. Biomeditsinskaia khimiia. 2016; 62 (4): 376–90. DOI: 10.18097/pbmc20166204376. PubMed PMID: 27562991.
  4. Gubanova NV, Gaytan AS, Razumov IA, Mordvinov VA, Krivoshapkin AL, Netesov SV, et al. Onkoliticheskie virusy v terapii gliom. Molecular Biology. 2012; 46 (6): 726–38.
  5. Csatary LK, Bakacs T. Use of Newcastle disease virus vaccine (MTH-68/H) in a patient with high-grade glioblastoma. JAMA. 1999; 281 (17): 588–589.
  6. Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther. 2000; 7 (10): 867–874.
  7. Csatary LK, Gosztonyi G, Szeberenyi J, Fabian Z, Liszka V, Bodey B, et al. MTH-68/H oncolytic viral treatment in human high- grade gliomas. J Neurooncol. 2004; 67 (1–2): 83–93.
  8. Iwadate Y, Inoue M, Saegusa T, Tokusumi Y, Kinoh H, Hasegawa M, et al. Recombinant Sendai virus vector induces complete remission of established brain tumors through efficient interleukin-2 gene transfer in vaccinated rats. Clin Cancer Res. 2005; 11 (10): 3821–27.
  9. Allen C, Opyrchal M, Aderca I, Schroeder MA, Sarkaria JN, Domingo E, et al. Oncolytic measles virus strains have significant antitumor activity against glioma stem cells. Gene Ther. 2012; 23 (10): 62.
  10. Alonso MM, Jiang H, Gomez-Manzano C, Fueyo J. Targeting brain tumor stem cells with oncolytic adenoviruses. Methods Mol Biol. 2012; 797: 111–125.
  11. Dey M, Ulasov IV, Lesniak MS. Virotherapy against malignant glioma stem cells. Cancer Lett. 2010; 289 (1): 1–10.
  12. Kanai R, Rabkin SD, Yip S, Sgubin D, Zaupa CM, Hirose Y, et al. Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells. J Natl Cancer Inst. 2012; 104 (1): 42–55.
  13. van den Hengel SK, Balvers RK, Dautzenberg IJ, van den Wollenberg DJ, Kloezeman JJ, Lamfers ML, et al. Heterogeneous reovirus susceptibility in human glioblastoma stem-like cell cultures. Cancer Gene Ther. 2013; 20(9): 507–513. DOI: 10.1038/ cgt.2013.47. PubMed PMID: 23907517.
  14. Zhu Z, Gorman MJ, McKenzie LD, Chai JN, Hubert CG, Prager BC, et al. Zika virus has oncolytic activity against glioblastoma stem cells. J Exp Med. 2017; 214 (10): 2843–57. DOI: 10.1084/ jem.20171093. PubMed PMID: 28874392; PubMed Central PMCID: PMCPMC5626408.
  15. Voroshilova MK. Potential use of nonpathogenic enteroviruses for control of human disease. Prog Med Virol. 1989; 36: 191–202. PubMed PMID: 2555836.